Silexion Therapeutics prices USD 2.5 million public offering at USD 0.65 per share with warrants
SLXN•Public offering priced with warrants
Silexion Therapeutics priced a USD 2.5 million public offering of 3,846,161 ordinary shares or equivalents with Series E warrants.
The combined offering price was set at USD 0.65 per share or equivalent, including accompanying warrants. The Series E warrants carry a USD 0.65 exercise price, are exercisable immediately, and expire five years from issuance.
Closing is expected on Aug. 13, 2026, subject to customary closing conditions.
Proceeds to support clinical trial and corporate purposes
Net proceeds are earmarked to advance the SIL204 clinical trial and fund general corporate purposes.
